800-401-4720
Recent Posts
Categories
Archives
Dangerous Drugs
Injuries
Contact Us
Dangerous Drugs and Injuiries Attorneys
Dangerous Drugs and Injuries Lawyers Who We Are What We Do Frequently Asked Questions Contact Us
We Sue Companies That Sell Dangerous Drugs
Nationwide Law Practice click here to be instantly connected to our office Medical and Legal News
1 entries found. Viewing page 1 of 1.  
September 09, 2010
  FDA Orders Label Changes for Gadolinium-Based Contrast Agents
Posted By DeCarli Law
The U.S. Food and Drug Administration (FDA) announced today that it will require significant label changes for gadolinium-based contrast agents (GBCAs) in order to reduce the risk of nephrogenic systemic fibrosis (NSF).

The most significant label change is the recommendation that Omniscan, Magnevist and Optimark NOT be used on people with chronic, severe kidney disease, such as dialysis patients, or those with acute kidney injury (AKI).  This follows the determination by FDA staff last fall that Omniscan, Magnevist and Optimark are the gadolinium-based contrast agents most likely to cause NSF.

The new labeling also recommends that healthcare professionals:
  • Screen patients prior to administration of a GBCA to identify those with AKI or chronic, severe, kidney disease.  These patients appear to be at highest risk for NSF.
  • Use the clinical history to screen patients for features of AKI or risk factors for chronically reduced kidney function.
  • Avoid use of GBCAs in patients suspected or known to have impaired drug elimination unless the need for the diagnostic information is essential and not available with non-contrasted MRI or other alternative imaging modalities.
  • Monitor for signs and symptoms of NSF after a GBCA is administered to a patient suspected or known to have impaired elimination of the drug.
  • Not repeat administration of any GBCA during a single imaging session.
The complete text of the FDA's Safety Announcement may be found HERE.

Unfortunately, this label change comes too late for some people with kidney disease or AKI who were injected with Omniscan, Magnevist and Optimark and as a result, developed NSF.  Symptoms of NSF include scaling, hardening and tightening of the skin; red or dark patches on the skin; and joint stiffness.  NSF can also cause fibrosis of internal organs that may lead to death.  There is no effective treatment for NSF.

If you or a loved one developed any of the NSF symptoms listed above after treatment with a gadolinium-based contrast agent, you may have a legal claim.  However, these and all personal injury claims are subject to statutes of limitations -- laws that place deadlines on when a claim may be made.  Call the NSF lawyers at DeCarli Law for a free, no-obligation telephone consultation to learn your legal options.  We are experienced helping people stricken with NSF, and can provide you with additional information about NSF and your legal rights.
Continue reading "FDA Orders Label Changes for Gadolinium-Based Contrast Agents" ยป

Permalink 
 
1 entries found. Viewing page 1 of 1.  
Attorney Web Design The information on this website is for general information purposes only. Nothing on this or associated pages, documents, comments, answers, emails, or other communications should be taken as legal advice for any individual case or situation. The information on this website is not intended to create, and receipt or viewing of this information does not constitute, an attorney-client relationship. DeCarli Law only represents individuals pursuant to a signed, written contract.

Address: 50 California Street, Suite 1500 San Francisco CA 94111 Toll Free: 1-800-401-4720 Phone: 1-415-738-6144
Debra DeCarli and Bob DeCarli are licensed by the State Bar of Texas and the State Bar of California.

DeCarli Law represents drug side effects and defective medical devices personal injury clients for claims, lawsuits and settlements in Alabama AL, Alaska AK, Arizona AZ, Arkansas AR, California CA, Colorado CO, Connecticut CT, Delaware DE, Georgia GA, Hawaii HI, Idaho ID, Illinois IL, Kansas KS, Maine ME, Maryland MD, Massachusetts MS, Minnesota MN, Mississippi MS, Montana MT, Nebraska NE, New Hampshire NH, New Jersey NJ, New Mexico NM, New York NY, North Carolina NC, North Dakota ND, Oklahoma OK, Oregon OR, Rhode Island RI, South Carolina SC, South Dakota SD, Tennessee TN, Utah UT, Vermont VT, Virginia VA, Washington WA, Washington D.C, West Virginia WV, Wisconsin WI and Wyoming WY. The attorneys of DeCarli Law are licensed in California and Texas. DeCarli Law's practice includes lawsuits for Propecia side effects, Finasteride lawsuits, Topamax lawsuits, Fosamax lawsuits, Gadolinium lawsuits, NSF lawsuits, Nephrogenic Systemic Fibrosis Lawsuits, YAZ lawsuits, Yasmin lawsuits, Ocella lawsuits, and Zarah lawsuits.